Pancreatic Ductal Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Pancreatic Ductal Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors [Phase 1, Phase 2]
Revolution Medicines is conducting a Phase 1/2 clinical trial of RAS(ON) inhibitors in gastrointestinal solid tumors, including colorectal c…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma [Phase 3]
Phase 3 trial evaluating Quemliclustat in combination with chemotherapy versus placebo with chemotherapy for metastatic pancreatic ductal ad…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours [Phase 1, Phase 2]
Ipsen is conducting a Phase 1/2 trial of IPN01194 as a single-agent therapy for adults with advanced solid tumors, currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating BMS-986504 plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine in u…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC
An exploratory clinical evaluation using personalized functional profiling to predict drug response in colorectal cancer and pancreatic duct…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating ONT01 in combination with gemcitabine and nab-paclitaxel as second-line therapy for metastatic pancreati…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors [Phase 1]
Phase 1 trial update on the safety of RAD301 in healthy volunteers and patients with pancreatic ductal adenocarcinoma or other solid tumors;…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Immunoparalysis After Pancreaticoduodenectomy
An ongoing clinical trial in Lyon is recruiting to study immunoparalysis after pancreaticoduodenectomy in patients with pancreatic ductal ad…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection [Phase 2]
Phase 2 trial assessing the imaging tracer 18F-FAPI-74 for cancer detection across multiple indications; currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [Phase 1, Phase 2]
An ongoing Phase 1/Phase 2 study evaluating an [18F]FPyQCP PET imaging agent targeting fibroblast activation protein across colorectal cance…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance [Phase 2]
A Phase 2 clinical trial evaluating ASP3082 in patients with metastatic or locally advanced non-small cell lung cancer and pancreatic ductal…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer [NA]
This entry reports a recruiting clinical trial investigating circulating tumor DNA (ctDNA) and circular DNA in patients with resectable panc…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer [NA]
This clinical trial outlines a screening program to improve early detection of pancreatic cancer in individuals at high risk and is currentl…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies [Phase 1, Phase 2]
This clinical trial update notes the completion of a Phase 1/2 study of ERAS-007 in patients with advanced gastrointestinal malignancies, sp…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2, Phase 3]
A clinical trial update for a study evaluating Telisotuzumab Adizutecan in combination with FOLFOX versus standard of care as first-line tre…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
A recruiting clinical trial (VAPOR2) led by Imperial College London studying volatile organic compound assessment in pancreatic cancer/PDAC.
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Clinical trial update indicating a study evaluating volatile organic compound assessment in pancreatic ductal adenocarcinoma is currently re…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: BBO-11818 in Adult Subjects With KRAS Mutant Cancer [Phase 1]
Phase 1 trial update for BBO-11818 in adults with KRAS-mutant cancers, currently recruiting across several KRAS-driven solid tumors includin…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma [EARLY_Phase 1]
Clinical trial update indicates the investigational agent OMO-103 is being studied in an early-phase trial for locally advanced or metastati…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer [Phase 1]
Phase 1 trial of NBTXR3 activated by radiation therapy for borderline resectable or locally advanced pancreatic cancer has been suspended.
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Fecal Microbial Transplants for the Treatment of Pancreatic Cancer [EARLY_Phase 1]
An early-phase trial is investigating fecal microbiota transplant as a treatment for pancreatic ductal adenocarcinoma and is currently recru…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma [EARLY_Phase 1]
An early-phase trial evaluating cholesterol-disruption in combination with standard of care for advanced pancreatic ductal adenocarcinoma; t…
-
CLINICAL_TRIALS other · 2026-03-19Clinical Trial Update: Autologous CAR-T Cells Targeting B7-H3 in PDAC [Phase 1]
An ongoing Phase 1 clinical trial is evaluating autologous CAR-T cells targeting B7-H3 for pancreatic cancer, and recruitment is currently o…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: IBI343 in Combination Therapy for Advanced Malignant Solid Tumors [Phase 2]
This is a Phase 2 clinical trial update for IBI343 in combination therapy targeting CLDN18.2-positive advanced solid tumors, including gastr…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification [Phase 1]
BeiGene is conducting a first-in-human Phase 1 study of BGB-53038, a pan-KRAS inhibitor, as a monotherapy or in combination, in participants…